{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:00:46Z","timestamp":1771934446639,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"DOI":"10.1186\/s42358-025-00514-y","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:27:39Z","timestamp":1767839259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytomegalovirus infection in patients with rheumatic disorders under rituximab treatment: a scoping review"],"prefix":"10.1186","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8061-5675","authenticated-orcid":false,"given":"Erta","family":"Rajabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4123-225X","authenticated-orcid":false,"given":"Kousha","family":"Farhadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6923-2040","authenticated-orcid":false,"given":"Hesam Aldin","family":"Varpaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6573-8556","authenticated-orcid":false,"given":"Maryam Sadat Fakhri","family":"Bafghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fateme","family":"Ghanbari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3500-4419","authenticated-orcid":false,"given":"Ali","family":"Afshari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9234-6919","authenticated-orcid":false,"given":"Abdolrahman","family":"Rostamian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1590-6396","authenticated-orcid":false,"given":"Hossein","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-7586","authenticated-orcid":false,"given":"Mohammadreza","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"12","key":"514_CR1","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","volume":"19","author":"P Griffiths","year":"2021","unstructured":"Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759\u201373.","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"514_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nri3552","volume":"13","author":"RS Hotchkiss","year":"2013","unstructured":"Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862\u201374.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"514_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.cmi.2022.05.034","volume":"28","author":"DSY Ong","year":"2022","unstructured":"Ong DSY, Chong G-LM, Chemaly RF, Cremer OL. Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression. Clin Microbiol Infect. 2022;28(10):1335\u201344.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"514_CR4","doi-asserted-by":"publisher","first-page":"e81881","DOI":"10.1371\/journal.pone.0081881","volume":"8","author":"L Pembrey","year":"2013","unstructured":"Pembrey L, Raynor P, Griffiths P, Chaytor S, Wright J, Hall AJ. Seroprevalence of cytomegalovirus, epstein barr virus and varicella Zoster virus among pregnant women in bradford: a cohort study. PLoS ONE. 2013;8(11):e81881.","journal-title":"PLoS ONE"},{"issue":"3","key":"514_CR5","doi-asserted-by":"publisher","first-page":"e2034","DOI":"10.1002\/rmv.2034","volume":"29","author":"M Zuhair","year":"2019","unstructured":"Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P. Estimation of the worldwide Seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Rev Med Virol. 2019;29(3):e2034.","journal-title":"Rev Med Virol"},{"issue":"6","key":"514_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/MOT.0b013e3282f0d386","volume":"12","author":"AJ Eid","year":"2007","unstructured":"Eid AJ, Razonable RR. Cytomegalovirus disease in solid organ transplant recipients: advances lead to new challenges and opportunities. Curr Opin Organ Transplant. 2007;12(6):610\u20137.","journal-title":"Curr Opin Organ Transplant"},{"issue":"10","key":"514_CR7","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1086\/514340","volume":"44","author":"AY Peleg","year":"2007","unstructured":"Peleg AY, Husain S, Qureshi ZA, Silveira FP, Sarumi M, Shutt KA, et al. Risk factors, clinical characteristics, and outcome of nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis. 2007;44(10):1307\u201314.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"514_CR8","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s00296-019-04324-6","volume":"39","author":"BJ Gardiner","year":"2019","unstructured":"Gardiner BJ, Haas EM, Bailey RC, Chow JK, Snydman DR. Reactivation of latent cytomegalovirus infection in patients with rheumatologic disease: a case-control study. Rheumatol Int. 2019;39(7):1229\u201340.","journal-title":"Rheumatol Int"},{"issue":"1","key":"514_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64(1):87\u201391.","journal-title":"Clin Infect Dis"},{"key":"514_CR10","doi-asserted-by":"crossref","unstructured":"Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol. 2019;10.","DOI":"10.3389\/fimmu.2019.01990"},{"issue":"3","key":"514_CR11","doi-asserted-by":"publisher","first-page":"e0229973","DOI":"10.1371\/journal.pone.0229973","volume":"15","author":"G Roberto","year":"2020","unstructured":"Roberto G, Spini A, Bartolini C, Moscatelli V, Barchielli A, Paoletti D, et al. Real word evidence on rituximab utilization: combining administrative and hospital-pharmacy data. PLoS ONE. 2020;15(3):e0229973.","journal-title":"PLoS ONE"},{"issue":"1","key":"514_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","volume":"149","author":"N Cooper","year":"2010","unstructured":"Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol. 2010;149(1):3\u201313.","journal-title":"Br J Haematol"},{"issue":"1","key":"514_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15\u201329.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"514_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection risks among patients with multiple sclerosis treated with Fingolimod, Natalizumab, Rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184\u201391.","journal-title":"JAMA Neurol"},{"issue":"7","key":"514_CR15","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of Immunoglobulin Levels, infectious Risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1(7):e184169.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"514_CR16","doi-asserted-by":"publisher","first-page":"e23455","DOI":"10.1002\/jcla.23455","volume":"34","author":"H Wang","year":"2020","unstructured":"Wang H, Yan S, Liu H, Li L, Song J, Wang G, et al. Infection risk in autoimmune hematological disorders with low-dose rituximab treatment. J Clin Lab Anal. 2020;34(10):e23455.","journal-title":"J Clin Lab Anal"},{"issue":"2","key":"514_CR17","first-page":"172","volume":"14","author":"K Gulleroglu","year":"2016","unstructured":"Gulleroglu K, Baskin E, Moray G, Ozdemir H, Arslan H, Haberal M. Rituximab therapy and infection risk in pediatric renal transplant patients. Exp Clin Transpl. 2016;14(2):172\u20135.","journal-title":"Exp Clin Transpl"},{"issue":"8","key":"514_CR18","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/1756-185X.13596","volume":"22","author":"Y Shi","year":"2019","unstructured":"Shi Y, Wu Y, Ren Y, Jiang Y, Chen Y. Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: A systematic review and meta-analysis. Int J Rheum Dis. 2019;22(8):1361\u201370.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"514_CR19","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","volume":"15","author":"T Kelesidis","year":"2011","unstructured":"Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis. 2011;15(1):e2\u201316.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"514_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","volume":"47","author":"JC Gea-Banacloche","year":"2010","unstructured":"Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47(2):187\u201398.","journal-title":"Semin Hematol"},{"issue":"13","key":"514_CR21","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1056\/NEJM200109273451315","volume":"345","author":"F Suzan","year":"2001","unstructured":"Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a Post-Transplantation lymphoproliferative disorder. N Engl J Med. 2001;345(13):1000.","journal-title":"N Engl J Med"},{"key":"514_CR22","first-page":"538137","volume":"2015","author":"T Hilal","year":"2015","unstructured":"Hilal T. Fatal cytomegalovirus disease after combination therapy with corticosteroids and rituximab for granulomatosis with polyangiitis. Case Rep Rheumatol. 2015;2015:538137.","journal-title":"Case Rep Rheumatol"},{"key":"514_CR23","doi-asserted-by":"publisher","first-page":"bcr2012006672","DOI":"10.1136\/bcr-2012-006672","volume":"2013","author":"L Le Clech","year":"2013","unstructured":"Le Clech L, Ianotto J-C, Quintin-Roue I, Tempescul A. Severe CMV complication following maintenance therapy with rituximab. BMJ Case Rep. 2013;2013:bcr2012006672.","journal-title":"BMJ Case Rep"},{"key":"514_CR24","doi-asserted-by":"crossref","unstructured":"Dybko J, Giordano U, Pilch J, Mizera J, Borkowski A, Dere\u0144-Wagemann I. Evaluating the impact of post-transplant cyclophosphamide and anti-thymocyte globulin on CMV reactivation following allogeneic hematopoietic stem cell transplantation: a systematic literature review. J Clin Med. 2023;12(24).","DOI":"10.3390\/jcm12247765"},{"issue":"1","key":"514_CR25","first-page":"Cd004759","volume":"1","author":"P Hill","year":"2017","unstructured":"Hill P, Cross NB, Barnett AN, Palmer SC, Webster AC. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cochrane Database Syst Rev. 2017;1(1):Cd004759.","journal-title":"Cochrane Database Syst Rev"},{"issue":"18","key":"514_CR26","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1016\/j.ejca.2009.08.010","volume":"45","author":"D Yahav","year":"2009","unstructured":"Yahav D, Gafter-Gvili A, Muchtar E, Skalsky K, Kariv G, Yeshurun M, et al. Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur J Cancer. 2009;45(18):3131\u201348.","journal-title":"Eur J Cancer"},{"issue":"1","key":"514_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19\u201332.","journal-title":"Int J Soc Res Methodol"},{"issue":"7","key":"514_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"key":"514_CR29","unstructured":"U.S. Food and Drug Administration. Rituxan (rituximab) injection, for intravenous use: Prescribing information. 2021."},{"key":"514_CR30","unstructured":"Genentech I. Rituxan (rituximab) injection, for intravenous use: Prescribing information. 2021."},{"key":"514_CR31","unstructured":"Agency EM. MabThera (rituximab): Product information. 2022."},{"issue":"2","key":"514_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/acr.22116","volume":"66","author":"M Bredemeier","year":"2014","unstructured":"Bredemeier M, de Oliveira FK, Rocha CM. Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(2):228\u201335.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"514_CR33","doi-asserted-by":"crossref","unstructured":"Harada M, Iwabuchi R, Yamaguchi A, Aomura D, Yamada Y, Sonoda K, et al. Predictive factors of cytomegalovirus viremia during the clinical course of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a single center observational study. J Clin Med. 2023;12(1).","DOI":"10.3390\/jcm12010351"},{"issue":"5","key":"514_CR34","first-page":"e38850","volume":"15","author":"R Ohta","year":"2023","unstructured":"Ohta R, Naito Y, Nishikura N, Inoue K, Sano C. Thrombocytopenia in Anti-neutrophil cytoplasmic Antibody-Associated vasculitis indicating the presence of cytomegalovirus infection: A case report. Cureus. 2023;15(5):e38850.","journal-title":"Cureus"},{"issue":"6","key":"514_CR35","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/mr\/roac150","volume":"33","author":"K Nagasaka","year":"2022","unstructured":"Nagasaka K, Amano K, Dobashi H, Nagafuchi H, Sada K-E, Komagata Y, et al. Nation-wide cohort study of remission induction therapy using rituximab in Japanese patients with antineutrophil cytoplasmic antibody\u2013associated vasculitis: effectiveness and safety in the first 6 months. Mod Rheumatol. 2022;33(6):1117\u201324.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"514_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1136\/ard.2011.153601","volume":"71","author":"JU Holle","year":"2012","unstructured":"Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener\u2019s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71(3):327\u201333.","journal-title":"Ann Rheum Dis"},{"key":"514_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaut.2014.03.002","volume":"50","author":"AL Calich","year":"2014","unstructured":"Calich AL, Pu\u00e9chal X, Pugnet G, London J, Terrier B, Charles P, et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener\u2019s). Results of a single-center cohort study on 66 patients. J Autoimmun. 2014;50:135\u201341.","journal-title":"J Autoimmun"},{"issue":"12","key":"514_CR38","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1111\/1756-185X.14929","volume":"26","author":"TY Hsieh","year":"2023","unstructured":"Hsieh TY, Chen MH, Wu CC, Hong WJ, Lu CH, Lu CC, et al. Rituximab induction and reinduction in granulomatosis with polyangiitis and microscopic polyangiitis: A retrospective multicenter study in Taiwan. Int J Rheum Dis. 2023;26(12):2441\u20139.","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"514_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1051\/mbcb\/2019006","volume":"25","author":"S Huang","year":"2019","unstructured":"Huang S, Delacroix I, Labrousse D. A rare case of cytomegalovirus induced oral ulcer in an immunocompromised patient. J Oral Med Oral Surg. 2019;25(3):22.","journal-title":"J Oral Med Oral Surg"},{"issue":"4","key":"514_CR40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3109\/14397595.2014.981945","volume":"25","author":"H Nagafuchi","year":"2015","unstructured":"Nagafuchi H, Atsumi T, Hatta K, Muso E, Takeno M, Yamada H, Ozaki S. Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis. Mod Rheumatol. 2015;25(4):603\u20138.","journal-title":"Mod Rheumatol"},{"key":"514_CR41","doi-asserted-by":"crossref","unstructured":"Tse JR, Ng GX. Pancytopenia secondary to cytomegalovirus reactivation. BMJ Case Rep. 2014;2014.","DOI":"10.1136\/bcr-2013-201857"},{"issue":"2","key":"514_CR42","first-page":"291","volume":"41","author":"T Shirai","year":"2023","unstructured":"Shirai T, Machiyama T, Sato H, Ishii T, Fujii H. Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis. Clin Exp Rheumatol. 2023;41(2):291\u2013300.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"514_CR43","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D Daoussis","year":"2017","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2017;46(5):625\u201331.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"514_CR44","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","volume":"72","author":"JE Gottenberg","year":"2013","unstructured":"Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, et al. Efficacy of rituximab in systemic manifestations of primary sjogren\u2019s syndrome: results in 78 patients of the autoimmune and rituximab registry. Ann Rheum Dis. 2013;72(6):1026\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"514_CR45","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3899\/jrheum.100818","volume":"38","author":"H VALLET","year":"2011","unstructured":"Vallet H, Houitte R, Azria A. Cytomegalovirus colitis and Hypo-IgG after rituximab therapy for rheumatoid arthritis. J Rhuematol. 2011;38(5):965\u20136.","journal-title":"J Rhuematol"},{"issue":"8","key":"514_CR46","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00277-016-2700-4","volume":"95","author":"T Jain","year":"2016","unstructured":"Jain T, John J, Kotecha A, Deol A, Saliminia T, Revankar S, Chandrasekar P. Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab. Ann Hematol. 2016;95(8):1323\u20137.","journal-title":"Ann Hematol"},{"key":"514_CR47","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/1471-2334-14-364","volume":"14","author":"JC Nissen","year":"2014","unstructured":"Nissen JC, Hummel M, Brade J, Kruth J, Hofmann WK, Buchheidt D, Reinwald M. The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience. BMC Infect Dis. 2014;14:364.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"514_CR48","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1080\/10428190701411441","volume":"48","author":"S Aksoy","year":"2007","unstructured":"Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, Barista I. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48(7):1307\u201312.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"514_CR49","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/ckj\/sfx038","volume":"10","author":"A Nixon","year":"2017","unstructured":"Nixon A, Ogden L, Woywodt A, Dhaygude A. Infectious complications of rituximab therapy in renal disease. Clin Kidney J. 2017;10(4):455\u201360.","journal-title":"Clin Kidney J"},{"key":"514_CR50","doi-asserted-by":"publisher","first-page":"e920681","DOI":"10.12659\/AJCR.920681","volume":"21","author":"E Alhassan","year":"2020","unstructured":"Alhassan E, Johnson J, Nakity R, Shah HZ. Rituximab use and hypogammaglobulinemia. Am J Case Rep. 2020;21:e920681.","journal-title":"Am J Case Rep"},{"issue":"5","key":"514_CR51","doi-asserted-by":"publisher","first-page":"e12732","DOI":"10.1111\/tid.12732","volume":"19","author":"Z Hakimi","year":"2017","unstructured":"Hakimi Z, Aball\u00e9a S, Ferchichi S, Scharn M, Odeyemi IA, Toumi M, Saliba F. Burden of cytomegalovirus disease in solid organ transplant recipients: a National matched cohort study in an inpatient setting. Transpl Infect Disease. 2017;19(5):e12732.","journal-title":"Transpl Infect Disease"},{"issue":"5","key":"514_CR52","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/jmv.23539","volume":"85","author":"H Harvala","year":"2013","unstructured":"Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol. 2013;85(5):893\u20138.","journal-title":"J Med Virol"},{"issue":"3","key":"514_CR53","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/tid.12537","volume":"18","author":"P Young","year":"2016","unstructured":"Young P, Rubin J, Angarone M, Flaherty J, Penugonda S, Stosor V, Ison M. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single\u2010center retrospective cohort study. Transpl Infect Disease. 2016;18(3):390\u20135.","journal-title":"Transpl Infect Disease"},{"key":"514_CR54","doi-asserted-by":"crossref","unstructured":"Linares L, Sanclemente G, Cervera C, Hoyo I, Cof\u00e1n F, Ricart M, et al., editors. Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant Proc. 2011; Elsevier.","DOI":"10.1016\/j.transproceed.2011.05.007"},{"issue":"2","key":"514_CR55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/tid.12036","volume":"15","author":"S Hammond","year":"2013","unstructured":"Hammond S, Martin S, Roberts K, Gabardi S, Fuhlbrigge A, Camp P, et al. Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis. Transpl Infect Disease. 2013;15(2):163\u201370.","journal-title":"Transpl Infect Disease"},{"key":"514_CR56","doi-asserted-by":"publisher","first-page":"8589402","DOI":"10.1155\/2019\/8589402","volume":"2019","author":"DK Yadav","year":"2019","unstructured":"Yadav DK, Hua YF, Bai X, Lou J, Que R, Gao S, et al. ABO-Incompatible adult living donor liver transplantation in the era of rituximab: A systematic review and Meta-Analysis. Gastroenterol Res Pract. 2019;2019:8589402.","journal-title":"Gastroenterol Res Pract"},{"issue":"6","key":"514_CR57","first-page":"573","volume":"13","author":"H Ishihara","year":"2015","unstructured":"Ishihara H, Ishida H, Toki D, Omoto K, Sirakawa H, Shimizu T, et al. Effects of Low-Dose rituximab therapy in patients with primary cytomegalovirus infection. Exp Clin Transpl. 2015;13(6):573\u201380.","journal-title":"Exp Clin Transpl"},{"issue":"2","key":"514_CR58","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ajh.22214","volume":"87","author":"F Marchesi","year":"2012","unstructured":"Marchesi F, Giannotti F, Avvisati G, Petti MC, Pimpinelli F, Paba P, et al. The potential role of pre-transplant HBcIgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: a study from the Rome transplant network. Am J Hematol. 2012;87(2):213\u20137.","journal-title":"Am J Hematol"},{"issue":"4","key":"514_CR59","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00277-007-0397-0","volume":"87","author":"MY Lee","year":"2008","unstructured":"Lee MY, Chiou TJ, Hsiao LT, Yang MH, Lin PC, Poh SB, et al. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin\u2019s lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol. 2008;87(4):285\u20139.","journal-title":"Ann Hematol"},{"issue":"2","key":"514_CR60","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1053\/j.seminhematol.2010.01.009","volume":"47","author":"K Dunleavy","year":"2010","unstructured":"Dunleavy K, Tay K, Wilson WH. Rituximab-associated neutropenia. Semin Hematol. 2010;47(2):180\u20136.","journal-title":"Semin Hematol"},{"issue":"1","key":"514_CR61","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000337577","volume":"5","author":"HS Kulkarni","year":"2012","unstructured":"Kulkarni HS, Kasi PM. Rituximab and cytokine release syndrome. Case Rep Oncol. 2012;5(1):134\u201341.","journal-title":"Case Rep Oncol"},{"issue":"5","key":"514_CR62","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.ekir.2025.02.002","volume":"10","author":"O Efe","year":"2025","unstructured":"Efe O, Sauvage G, Jeyabalan A, Al Jurdi A, Seethapathy HS, Cosgrove K, et al. Persistent B cell depletion after rituximab for autoimmune and glomerular diseases: A case series. Kidney Int Rep. 2025;10(5):1441\u20139.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"514_CR63","doi-asserted-by":"publisher","first-page":"20926","DOI":"10.1038\/s41598-022-25451-4","volume":"12","author":"T Shimada","year":"2022","unstructured":"Shimada T, Higashida-Konishi M, Izumi K, Hama S, Oshige T, Oshima H, Okano Y. Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study. Sci Rep. 2022;12(1):20926.","journal-title":"Sci Rep"},{"issue":"11","key":"514_CR64","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/art.40937","volume":"71","author":"MY Md Yusof","year":"2019","unstructured":"Md Yusof MY, Vital EM, McElvenny DM, Hensor EMA, Das S, Dass S, et al. Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2019;71(11):1812\u201323.","journal-title":"Arthritis Rheumatol"},{"key":"514_CR65","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","volume":"54","author":"S Tavakolpour","year":"2018","unstructured":"Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review. Int Immunopharmacol. 2018;54:131\u20138.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"514_CR66","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/bjd\/ljac118","volume":"188","author":"K Kridin","year":"2023","unstructured":"Kridin K, Mruwat N, Amber KT, Ludwig RJ. Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. Br J Dermatol. 2023;188(4):499\u2013505.","journal-title":"Br J Dermatol"},{"issue":"7","key":"514_CR67","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","volume":"80","author":"A Strangfeld","year":"2021","unstructured":"Strangfeld A, Sch\u00e4fer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"514_CR68","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.16896","volume":"190","author":"PR Tepasse","year":"2020","unstructured":"Tepasse PR, Hafezi W, Lutz M, Kuehn J, Wilms C, Wiewrodt R, et al. Persisting SARS-CoV\u20102 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol. 2020;190(2):185\u20138.","journal-title":"Br J Haematol"},{"issue":"1","key":"514_CR69","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/ajt.13444","volume":"16","author":"G-W Song","year":"2016","unstructured":"Song G-W, Lee S-G, Hwang S, Kim K-H, Ahn C-S, Moon D-B, et al. ABO-incompatible adult living donor liver transplantation under the desensitization protocol with rituximab. Am J Transplant. 2016;16(1):157\u201370.","journal-title":"Am J Transplant"},{"issue":"10","key":"514_CR70","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1111\/j.1600-6143.2006.01497.x","volume":"6","author":"H Genberg","year":"2006","unstructured":"Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant. 2006;6(10):2418\u201328.","journal-title":"Am J Transplant"},{"issue":"7","key":"514_CR71","doi-asserted-by":"publisher","first-page":"e0181590","DOI":"10.1371\/journal.pone.0181590","volume":"12","author":"KY Lee","year":"2017","unstructured":"Lee KY, Yoo BW, Ahn SS, Bae WH, Lee H, Jung SM, et al. Predictors of mortality in autoimmune disease patients with concurrent cytomegalovirus infections detected by quantitative real-time PCR. PLoS ONE. 2017;12(7):e0181590.","journal-title":"PLoS ONE"},{"issue":"6","key":"514_CR72","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.55563\/clinexprheumatol\/pqa98i","volume":"39","author":"Y Ota","year":"2021","unstructured":"Ota Y, Kaneko Y, Takeuchi T. Association between mortality and cytomegalovirus reactivation during remission induction therapy in patients with rheumatic diseases. Clin Exp Rheumatol. 2021;39(6):1324\u201330.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"514_CR73","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/rheumatology\/kead328","volume":"63","author":"LD Veeken","year":"2024","unstructured":"Veeken LD, Opdam MAA, Verhoef LM, Popa C, van Crevel R, den Broeder AA. Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study. Rheumatology (Oxford). 2024;63(5):1246\u201350.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"514_CR74","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1016\/S2665-9913(19)30066-9","volume":"1","author":"LM Verhoef","year":"2019","unstructured":"Verhoef LM, den Broeder N, Thurlings RM, van der Laan WH, van der Weele W, Kok MR, et al. Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial. Lancet Rheumatol. 2019;1(3):e145\u201353.","journal-title":"Lancet Rheumatol"},{"key":"514_CR75","doi-asserted-by":"publisher","first-page":"971366","DOI":"10.3389\/fimmu.2022.971366","volume":"13","author":"Y Gan","year":"2022","unstructured":"Gan Y, Zhong X, Zhao Y, Li G, Ye H, Li C. Low dose versus standard dose rituximab for the treatment of antiphospholipid syndrome: A pilot study from a tertiary medical center. Front Immunol. 2022;13:971366.","journal-title":"Front Immunol"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-025-00514-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00514-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00514-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:04:36Z","timestamp":1771931076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42358-025-00514-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["514"],"URL":"https:\/\/doi.org\/10.1186\/s42358-025-00514-y","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}